Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SUTRO BIOPHARMA, INC.
Report date May 15, 2025 · Filed May 19, 2025
Section 16 reporting ended · disclosed 2025-05-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,805 |
Ending reported balance
After 2025-05-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-05-15 · Exercise / conversion · Acquired 24,438 · Balance 156,519 Row 2 · 2025-05-15 · Exercise / conversion · Acquired 11,156 · Balance 167,675 Row 3 · 2025-05-15 · Exercise / conversion · Acquired 9,125 · Balance 176,800 Row 4 · 2025-05-15 · Tax withholding · Disposed 15,995 · Balance 160,805 F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2028-03-01 | Direct | 27,312 |
Reported balance
After 2025-05-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-05-15 · Exercise / conversion · Disposed 24,438 · Balance 27,312 F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. F4: The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with his separation and transition from his position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2027-03-01 | Direct | 4,594 |
Reported balance
After 2025-05-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-05-15 · Exercise / conversion · Disposed 11,156 · Balance 4,594 F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4: The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with his separation and transition from his position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025. F5: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2026-03-04 | Direct | 0 |
Reported balance
After 2025-05-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-05-15 · Exercise / conversion · Disposed 9,125 · Balance 0 F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4: The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with his separation and transition from his position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025. F6: The RSUs vest as to 1/4th of the total award annually beginning on March 4, 2023, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F3: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date.
F4: The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with his separation and transition from his position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025.
F5: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date.
F6: The RSUs vest as to 1/4th of the total award annually beginning on March 4, 2023, subject to continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 29, 2022 Filed Feb 1, 2022 20:31 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006119 · doc4.xml · derivative · entry 3 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 5,250 shares Expires 2025-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 20:31 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,151 | $10.39 | $22,348.89 |
DisclosureSEC source: 0001209191-22-006119 · doc4.xml · nonDerivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,993 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 20:31 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006119 · doc4.xml · nonDerivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 18:53 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 7,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057975 · doc4.xml · derivative · entry 3 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,174 shares Expires 2021-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 18:53 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,480 | $19.23 | $47,690.40 |
DisclosureSEC source: 0001209191-21-057975 · doc4.xml · nonDerivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,894 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 18:53 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 7,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057975 · doc4.xml · nonDerivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 17:16 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018617 · doc4.xml · derivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2025-03-05 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 17:16 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 50,000 | $0.00 Strike: $21.11 | $0.00 |
DisclosureSEC source: 0001209191-21-018617 · doc4.xml · derivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-03-04 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on April 5, 2021, with 100% of the total shares vested and exercisable on March 5, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 17:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-006550 · doc4.xml · derivative · entry 3 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 5,250 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 17:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,126 | $22.15 | $47,090.90 |
DisclosureSEC source: 0001209191-21-006550 · doc4.xml · nonDerivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,200 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 17:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-006550 · doc4.xml · nonDerivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:52 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 7,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052243 · doc4.xml · derivative · entry 3 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,174 Underlying: Common Stock · 7,174 shares Expires 2021-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:52 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,480 | $10.30 | $25,544.00 |
DisclosureSEC source: 0001209191-20-052243 · doc4.xml · nonDerivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,076 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:52 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 7,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052243 · doc4.xml · nonDerivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 17:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005798 · doc4.xml · derivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2024-01-29 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 17:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 47,500 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001209191-20-005798 · doc4.xml · derivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2030-01-29 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 29, 2020, with 100% of the total shares vested and exercisable on January 29, 2024, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:18 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 7,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051116 · doc4.xml · derivative · entry 3 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,348 Underlying: Common Stock · 7,174 shares Expires 2021-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:18 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,480 | $9.74 | $24,155.20 |
DisclosureSEC source: 0001209191-19-051116 · doc4.xml · nonDerivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,382 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:18 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 7,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051116 · doc4.xml · nonDerivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:07 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 47,500 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001209191-19-006200 · doc4.xml · derivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 28, 2019, with 100% of the total shares vested and exercisable on January 29, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:08 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionSeries D Preferred Stock · Derivative | 41,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052826 · doc4.xml · derivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,688 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended, and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended, and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended, and had no expiration date. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:08 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionCommon Stock | 1,688 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052826 · doc4.xml · nonDerivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended, and had no expiration date. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 17:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 21,522 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052476 · doc4.xml · derivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,522 Underlying: Common Stock · 21,522 shares Expires 2021-09-25 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 17:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 129,132 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052476 · doc4.xml · derivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,132 Underlying: Common Stock · 129,132 shares Expires 2028-09-25 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on October 26, 2018, with 100% of the total shares vested and exercisable on September 26, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.